Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01710332 · ClinicalTrials.gov registry record · Phase 2
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
A Phase 2 study of Central Serous Chorioretinopathy, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT01710332 is a Phase 2 study of Central Serous Chorioretinopathy that has completed, run by Wills Eye. The registered enrollment target is 12 participants, below the 87-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01710332, a Phase 2 study of Central Serous Chorioretinopathy, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
A preliminary study to determine the safety and efficacy of intravitreal aflibercept injection in patients with persistent central serous chorioretinopathy.
Conditions Studied
Interventions
- DRUG Intravitreal Aflibercept Injection
Study Locations (2)
Pennsylvania
- Mid Atlantic Retina- Huntingdon Valley - Huntingdon Valley
- Mid Atlantic Retna- Wills Eye Institute - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01710332
The ClinicalTrials.gov registry entry for NCT01710332 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (86% lower). The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Serous Chorioretinopathy appearing as the primary indexed condition, and to 1 intervention - of which Intravitreal Aflibercept Injection is the first listed.
NCT01710332 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01710332 about?
NCT01710332 is a clinical study titled "The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy". A preliminary study to determine the safety and efficacy of intravitreal aflibercept injection in patients with persistent central serous chorioretinopathy.
What is the current status of trial NCT01710332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2012-10. Estimated completion is 2013-06.
What conditions does trial NCT01710332 study?
This clinical trial studies the following conditions: Central Serous Chorioretinopathy.
What interventions are being tested in trial NCT01710332?
The interventions under investigation include: Intravitreal Aflibercept Injection (DRUG).
Who is sponsoring clinical trial NCT01710332?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01710332 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Serous Chorioretinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
COMPLETED · Phase 2
-
OCT in Rare Chorioretinal Diseases
RECRUITING
-
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
COMPLETED
-
Eplerenone for the Treatment of Central Serous Chorioretinopathy
COMPLETED · NA
-
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.